COMP360 psilocybin treatment holds Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

From the articleLatest Company News - Investing.comAlso in Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day